![]() |
Trastuzumab should remain as standard of care for HER2-positive breast cancer
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that...
More... |
| All times are GMT -7. The time now is 06:26 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021